Navigation Links
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
Date:6/13/2008

dpoint. The fact that significance has been observed in a single trial supports our confidence that a clear statistical differentiation will be obtained between naproxcinod and naproxen in the predefined pooled analysis of the OBPM data."

Two remaining phase 3 trials for naproxcinod are currently ongoing (the 302 and 303 studies) and their results are anticipated in the second half of 2008. Naproxcinod's effect on blood pressure, in comparison to naproxen and placebo, will also be assessed by OBPM in these trials, allowing NicOx to perform a predefined statistical analysis on the pooled OBPM data. NicOx projects the filing of a New Drug Application (NDA) for naproxcinod in mid-2009.

Results of the blood pressure analysis

At week 13, naproxcinod showed mean changes from baseline in systolic blood pressure, compared to naproxen, of minus 2.89 mmHg (p<0.05) for the 750 mg bid dose and -1.82 mmHg (p=0.12) for the 375 mg bid dose. For diastolic blood pressure, in terms of mean changes from baseline compared to naproxen, naproxcinod 750 mg bid was -1.79 mmHg (p<0.05) and naproxcinod 375 mg bid was -1.55 mmHg (p<0.05). At the week 13 time point, more individual patients on naproxcinod showed a decrease in blood pressure compared to patients on placebo and naproxen.

Assessment of efficacy in the trial

The presentation contains additional information on the efficacy outcome measures of the study, going beyond the top-line results announced in 2006 (see press release of October 27, 2006). The detailed results for the two doses of naproxcinod, naproxen and placebo on the WOMAC(TM) pain subscale, WOMAC(TM) function subscale and patients' overall rating of disease status, at 2, 6 and 13 weeks are being displayed in graphical form. The three co-primary endpoints of the study assessed these scores at 13 weeks, in comparison to baseline. Sensitivity and subgroup analyses confirmed the positive result on these co-primary endpoints. Additional effic
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
2. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
3. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
4. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
7. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
8. NicOx Naproxcinod ABPM Data Presented at American Heart Association
9. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
10. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
11. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015  NanoSmart ... drug delivery platforms, has received Orphan Drug Designation ... a second drug product that uses NanoSmart,s proprietary ... formulation of dactinomycin for the treatment of Ewing,s ... The FDA granted NanoSmart,s Orphan Drug Designation on ...
(Date:7/30/2015)...  Cleave Biosciences today announced that the United ... company a key patent providing the protection of ... This newly issued patent, "Fused pyrimidines and ... allows for claims on the composition of matter ... of p97, a critical enzyme that controls various ...
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2
... , MOUNTAIN VIEW, Calif., Dec. 18 ... of Ruediger Naumann-Etienne to its Board of Directors. , "Rudi ... medical device companies," said Theodore A. Boutacoff, President and CEO ... & Quist followed by CEO/President positions with Diasonics, OEC Medical ...
... Dec. 18 Eli Lilly and Company (NYSE: ... and chief financial officer for Lilly, has assumed expanded responsibilities ... and chief financial officer, effective January 1. , In ... officer of the company and add responsibility for global services, ...
Cached Medicine Technology:Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors 2Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors 3Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President 2
(Date:7/30/2015)... ... 30, 2015 , ... Boston Web Marketing is ... Google Partners is the platform for search marketing agencies to communicate with the ... necessary to run successful search marketing campaigns. Google Partners also affords businesses the ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ocean Hills Recovery has officially been accredited ... “no recommendations.” No recommendations means CARF found no areas in the OHR program that ... than 3% of all facilities receive. In addition, Ocean Hills was granted the maximum ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... National Cancer Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn ... (NCI)-designated cancer center. TCI joins an elite group of 69 cancer institutions nationwide ...
(Date:7/30/2015)... ... 30, 2015 , ... 1Heart Caregiver Services LLC is offering its 1st Business ... in the Booming Homecare Business.” This will be held in its main headquarters at ... event will be hosted by 1Heart’s very own Randy Clarito (Director of Business and ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Summer is ... hot spots.”* Add to that a particularly long, dry and hot 2015 summer season ... host and fresh water advocate Sharon Kleyne will discuss the 2015 summer season and ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3
... at the Medical Research Council have identified changes in ... in the esophagus, a condition called Barrett,s dysplasia, making ... before they develop into esophageal cancer. These findings, reported ... implications for patients and may help to monitor their ...
... new technology developed by neuroscientists at Cold Spring Harbor Laboratory ... made of whole brains. Until now, means of obtaining ... mammalian brain -- have been painstakingly slow and available only ... By automating and standardizing the process in which brain samples ...
... (HealthDay News) -- When women seem scarce, men may compete ... according to a new study. "What we see in ... more competitive. They compete more for access to mates," lead ... Carlson School of Management at the University of Minnesota, said ...
... FRIDAY, Jan. 13 (HealthDay News) -- Health and fitness experts ... by flogging long-range benefits such as losing weight or avoiding ... been going about it all wrong. Research now appears to ... effective message than "feel better now." A University of ...
... indices to identify patients with symptoms associated with ovarian cancer who ... the US in an attempt to promote earlier diagnosis, but they ... cancer, according to a study published January 13 in the ... cancer is a disease which is perceived to rarely produce symptoms ...
... wearing contact lenses affects glaucoma measurements has been named ... of Medicine,s annual St. Albert,s Day research symposium. ... fourth-year student at Stritch School of Medicine. Brenner ... on retinal nerve fiber layer measurements, which ophthalmologists use ...
Cached Medicine News:Health News:Researchers use sugar to halt esophageal cancer in its tracks 2Health News:CSHL team introduces automated imaging to greatly speed whole-brain mapping efforts 2Health News:CSHL team introduces automated imaging to greatly speed whole-brain mapping efforts 3Health News:Do Men Flash Cash to Find a Mate? 2Health News:Need to Exercise More? Think How It Will Help You Now 2Health News:Need to Exercise More? Think How It Will Help You Now 3Health News:Predicting the value of indexing symptoms for ovarian cancer 2
... Eliminate the need for makeshift, modified ... Why waste time gathering parts when your ... need to deliver the utmost in Heliox ... therapy is fast becoming the standard of ...
... has been developing diverse medical ... years. Our medical-surgical products have ... innovation, quality and customer satisfaction. ... the Labtron® line of diagnostic ...
... nebulizer utilizing Vibrating Mesh Technology to ... suffering from Asthma, COPD or other ... product size and handy carrying case ... takes them. Powerful delivery comparable to ...
... deliver particulate humidity in the 3 to ... patients. For your convenience, Thera-Mist® nebulizers may ... sterile water., ,The P30000N, for normal ... with a total flow range of 68-24 ...
Medicine Products: